International Journal of Research Foundation of Hospital and Healthcare Administration

Register      Login

VOLUME 6 , ISSUE 2 ( July-December, 2018 ) > List of Articles

REVIEW ARTICLE

Pharmacovigilance: Present Scenario and Future Goals

AK Mohiuddin

Keywords : Medicine, Monitoring, Pharmacists, Prevention, Safety,Adverse drug reactions

Citation Information : Mohiuddin A. Pharmacovigilance: Present Scenario and Future Goals. Int J Res Foundation Hosp Healthc Adm 2018; 6 (2):91-98.

DOI: 10.5005/jp-journals-10035-1098

License: CC BY-NC 4.0

Published Online: 00-12-2018

Copyright Statement:  Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Pharmacovigilance is the science and activities associated with gathering, recognition, appraisal, checking, and counteractive action of untoward impacts with pharmaceutical items. Pharmacovigilance essentially safety of medicine. Pharmacists have key roles in wellbeing frameworks to keep up the reasonable and safe utilization of medicine for they are medicated specialists who are unequivocally prepared in this field. The perspective of drug store understudies on pharmacovigilance and adverse drug reaction (ADR) revealing has additionally been examined with an intend to center the need to improve content identified with ADR announcing and pharmacovigilance in undergrad drug store educational programs. Globally, despite the fact that the job of pharmacists inside national pharmacovigilance frameworks contrasts, it is exceptionally all around perceived. Reconciliation of ADR announcing ideas in instruction educational modules, preparing of pharmacists and deliberate commitment of pharmacists in ADR revealing is imperative in accomplishing the safety objectives and preservation of general wellbeing. Likewise, these learning holes can be placed through nonstop expert improvement projects and fortifying hypothetical and reasonable information in undergrade drug store educational programs. Without adequately distinguishing and acknowledging preparing requirements of pharmacists and other human services experts, the capability of national pharmacovigilance frameworks is probably not going to enhance which may trade off patient\'s safety. Purpose: Discussion and projection of present situation analysis and future demand for pharmacovigilance. The pharmacists have a vital role to play which is thoroughly discussed. Methodology: Research conducted a year-round comprehensive literature search, which included technical newsletters, newspapers journals, and many other sources. The present study was started at the beginning of 2018. PubMed, ALTAVISTA, Embase, Scopus, Web of Science, and the Cochrane Central Register of was thoroughly searched. The keywords were used to search for different publishers’ journals like Elsevier, Springer, Willey Online Library, Wolters Kluwer extensively were followed. Medicine and technical experts, pharma company delegates, hospital nurses and chemists were given their valuable suggestions. Predictions were based on estimates such as drug end users, providers or prescribers, general knowledge of rational use, consequence and types of different incidences of ADR and non-compliance, their management or overlooking. Studies regarding inclusion and information sources of pharmacovigilance were given priorities. Several factors that influence medication-taking behavior, non-compliance, ADR reporting by pharmacists were communally analyzed and added to the article. Issues regarding economic and cultural barriers were found to be different from subcontinents, countries and even states. Most significant features of pharmacists’ role in the therapeutic intervention were added afterward to maintain a logical sequence. Drug factors, environmental factors and provider-patient interaction followed by pharmacist\'s role in handling patients and to change or correction of medication counseling, dispensing, monitoring was added to reveal their effect on patient compliance which is the eventual goal of meeting therapeutic guidelines. Many studies found regarding pharmacists’ role in therapeutic cost minimization, role in hospital and other healthcare settings, disease prevention, and lifestyle management found to be not within the scope of this article. Findings: Pharmacists are an integral part of the healthcare management system, and the importance of their role play is not after doctors and nurses. Any future role for the pharmacist in counseling, monitoring and vigilance could be addressed as part of a formalized, strategic approach by creating an integrated healthcare team, with attention to further enhancement of pharmacovigilance in any country, community or a healthcare setting. Research limitations: Research has a major limitation with dealing too many information on pharmacovigilance worldwide. An only important aspect of the expanded role of pharmacists, the present situation of vigilance in different countries and a few future prospect, demand and provisions of pharmacists in meeting those emerging demands are discussed. Practical implication: The soul of this article was to detail about the present situation and future demands of pharmacovigilance. Along with students, researchers and professionals of different background and disciplines, e.g., pharmacists, marketers, doctors, nurses, hospital authorities, public representatives, policy makers, and regulatory authorities have to acquire much from this article. Social implication: The article should contribute an integrated guideline for patient compliance, demand pharmacovigilance and last but not the least a silver lining of better healthcare situation in near future.


PDF Share
  1. Öztürk AB, Özyiðit LP, Þener Ü, Özyýldýrým A, Ýliaz S, Çaðlayan B, et al. Reporting Adverse Drug Reactions in a Tertiary Care Hospital in Ýstanbul. Turk Thorac J. 2018;19(4):237-239.
  2. Ribeiro MR, Motta AA, Marcondes-Fonseca LA, Kalil-Filho J, Giavina-Bianchi P. Increase of 10% in the Rate of Adverse Drug Reactions for Each Drug Administered in Hospitalized Patients. Clinics (Sao Paulo). 2018;73:e185.
  3. Parameswaran Nair N, Chalmers L, Peterson GM, Bereznicki BJ, Castelino RL, Bereznicki LR. Hospitalization in older patients due to adverse drug reactions -the need for a prediction tool. Clin Interv Aging. 2016;11:497-505.
  4. Ruscin JM, Linnebur SA. Aging and Drugs. Merck Manual Consumer Version. © 2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
  5. Chopra D, Rehan HS, Sharma V, Mishra R. Chemotherapyinduced adverse drug reactions in oncology patients: A prospective observational survey. Indian J Med Paediatr Oncol. 2016 Jan-Mar;37(1):42-46.
  6. Inácio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2016;83(2):227-246.
  7. Al Dweik R, Stacey D, Kohen D, Yaya S. Factors affecting patient reporting of adverse drug reactions: a systematic review. Br J Clin Pharmacol. 2016;83(4):875-883.
  8. Gurmesa LT, Dedefo MG. Factors Affecting Adverse Drug Reaction Reporting of Healthcare Professionals and Their Knowledge, Attitude, and Practice towards ADR Reporting in Nekemte Town, West Ethiopia. Biomed Res Int. 2016;2016:5728462.
  9. Avong YK, Jatau B, Gurumnaan R, Danat N, Okuma J, Usman I, et al. Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study. PLoS One. 2018;13(8):e0200810. 2018 Aug 22.
  10. O'Callaghan J, Griffin BT, Morris JM, Bermingham M. Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland. Bio Drugs. 2018;32(3): 267-280.
  11. Hohl CM, Small SS, Peddie D, Badke K, Bailey C, Balka E. Why Clinicians Don't Report Adverse Drug Events: Qualitative Study. JMIR Public Health Surveill. 2018;4(1):e21. 2018 Feb 27.
  12. Gifford ML, Anderson JE. Barriers and motivating factors in reporting incidents of assault in mental health care. J Am Psychiatr Nurses Assoc. 2010 Sep;16(5):288-298.
  13. Ferner RE, Easton C, Cox AR. Deaths from Medicines: A Systematic Analysis of Coroners’ Reports to Prevent Future Deaths. Drug Saf. 2018 Jan;41(1):103-110.
  14. Giardina C, Cutroneo PM, Mocciaro E, Russo GT, Mandraffino G, Basile G, et al. Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. Frontiers in pharmacology. 2018 Apr 11;9:350.
  15. Chu DK, Kim LH, Young PJ, Zamiri N, Almenawer SA, Jaeschke R, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018 Apr 28;391(10131):1693-1705.
  16. Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007;6(11):904-916.
  17. Angiji A. Adverse Drug Reactions related to mortality and morbidity: Drug - drug interactions and overdoses.
  18. Hillman D, Mitchell S, Streatfeild J, Burns C, Bruck D, Pezzullo L. The economic cost of inadequate sleep. Sleep. 2018 Jun 4;41(8):zsy083.
  19. Hartman J, Härmark L, van Puijenbroek E. A global view of undergraduate education in pharmacovigilance. Eur J Clin Pharmacol. 2017;73:891-899.
  20. Abubakar AR, Haque M. Pharmacovigilance practice: the current challenges and the gaps in the medical students’ curriculum. J App Pharm Sci. 2016;6(05):210-215.
  21. Gavaza P, Bui B. Pharmacy students’ attitudes toward reporting serious adverse drug events. Am J Pharm Educ. 2012;76(10):194.
  22. De Angelis A, Colaceci S, Giusti A, Vellone E, Alvaro R. Factors that condition the spontaneous reporting of adverse drug reactions among nurses: an integrative review. J Nurs Manag. 2015;23(4):1-13.
  23. Pagotto C, Varallo F, Mastroianni P. Impact of educational interventions on adverse drug events reporting. Int J Technol Assess Health Care. 2013;29(4):410-417.
  24. Rutter P, Brown D, Howard J, Randall C. Pharmacists in pharmacovigilance: can increased diagnostic opportunity in community settings translate to better vigilance? Drug Saf. 2014;37(7):465-469.
  25. Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting: a critical and systematic review. Drug Saf. 2013;36(5): 317-328.
  26. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19-31.
  27. Inman WH. Attitudes to adverse drug reaction reporting. Br J Clin Pharmacol. 1996;41(5):434-435.
  28. De Angelis A, Colaceci S, Giusti A, Vellone E, Alvaro R. Factors that condition the spontaneous reporting of adverse drug reactions among nurses: an integrative review. Journal of nursing management. 2016 Mar;24(2):151-163.
  29. Herdeiro MT, Ribeiro-Vaz I, Ferreira M, Polnia J, Falco A, Figueiras A. Workshop-and telephone-based interventions to improve adverse drug reaction reporting: a clusterrandomized trial in Portugal. Drug Saf. 2012;35(8):655-665.
  30. Johansson-Pajala RM, Martin L, Fastbom J, Blomgren KJ. Nurses’ self-reported medication competence in relation to their pharmacovigilant activities in clinical practice. J Eval Clin Pract. 2015;21(1):145-152.
  31. Ribeiro-Vaz I, Santos CC, Cruz-Correia R. Promoting adverse drug reaction reporting: comparison of different approaches. Rev Saude Publica. 2016;50:14.
  32. Ribeiro-Vaz I, Herdeiro MT, Polónia J, Figueiras A. Strategies to increase the sensitivity of pharmacovigilance in Portugal. Revista de saude publica. 2011 Feb;45(1):129-135.
  33. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol. 1998;45(5):427-431.
  34. WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy 2000-2003.
  35. Olsson S. The role of the WHO Programme for International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998;19:1-10.
  36. Coulter DM. The New Zealand intensive medicines monitoring programme in proactive safety surveillance. Pharmacoepidemiol Drug Saf. 2000;9:273-280.
  37. Moore N. The role of the clinical pharmacologist in the management of ADRs. Drug Saf. 2001;24:1-7.
  38. Hornbuckle K, Wu HH, Fung MC. Evaluation of spontaneous adverse event reports by primary reporter: A 15-year review (1983 to 1997) Drug Inf J. 1999;33:1117-1124.
  39. Mahmood KT, Amin F, Tahir M, Haq IU. Pharmacovigilance-A need for best patient care in Pakistan. A review. Journal of Pharmaceutical Sciences and Research. 2011 Nov 1;3(11): 1566-1584.
  40. Uppsala Monitoring Centre (UMC) Web. WHO Collaborating Centres 2017; Nov 13.
  41. WHO Web. The Importance of Pharmacovigilance–Safety Monitoring of Medicinal Products 2002. Essential Medicines and Health Products Information Portal A World Health Organization resource.
  42. Peabody J, Acelajado MC, Robert T, Hild C, Schrecker J, Paculdo D, Tran M, Jeter E. Drug-drug interaction assessment and identification in the primary care setting. Journal of clinical medicine research. 2018 Nov;10(11):806-814.
  43. Ansari J. Drug interaction and pharmacist. J Young Pharm. 2010;2(3):326-331.
  44. Yeh YT, Hsu MH, Chen CY, Lo YS, Liu CT. Detection of potential drug-drug interactions for outpatients across hospitals. Int J Environ Res Public Health. 2014;11(2):1369-1383.
  45. Shah RR. Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics. Drug Saf Case Rep.2017;4(1):11.
  46. Bowles Jr GC. Adverse drug reaction reporting urged as factor in accreditation. Mod Hosp. 1964;103:120.
  47. Latif A, Helen P, Boardmana F. The contribution of the Medicines Use Review (MUR) consultation to counseling practice in community pharmacies. Patient Education and Counseling 2011 June 83(3):336-344.
  48. Van Grootheest AC, De Jong-van den Berg LT. The role of hospital and community pharmacists in pharmacovigilance. Res Social Adm Pharm. 2005 Mar;1(1):126-133.
  49. APhA. Principles of Practice for Pharmaceutical Care. © Copyright 2018, American Pharmacists Association.
  50. Mohiuddin AK. Patient Compliance: An Untold Story or a Fairy Tale. Pharmaceut Reg Affairs. 2018;7(2):207.
  51. Kumar B, Khare DP, Shafaat K, Yadav VK, Kumar U. Professional scopes and roles of community pharmacists in various health care services: An updated review. Journal of Pharmacy Research 2011,4(5):1331-1335.
  52. Bhaskaran S. A vision of Indian pharmacist in 2020. PHARMABIZ.com December 16, 2010.
  53. Toklu HZ, Mensah E. Why do we need pharmacists in pharmacovigilance systems?. Online J Public Health Inform. 2016;8(2):e193.
  54. Management Sciences for Health (www.msh.org). Chapter 33. Encouraging appropriate medicine use by consumers.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.